New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2014
08:25 EDTCDXC, CDXC, SNTI, SNTI, ETAK, ETAK, TWER, TWER, ANDA, ANDA, SFE, SFE, ABMD, ABMD, TALN, TALN, AXGN, AXGN, PED, PEDNoble Financial Capital Markets to host a conference
10th Annual Equity Conference is being held in Sandpiper Bay, Florida on January 19-22 with webcasted company presentations to begin on January 22 at 8:30 am; not all company presentations may be webcasted. Webcast Link
News For CDXC;AXGN;TALN;ABMD;SFE;ANDA;TWER;ETAK;SNTI;PED From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
11:03 EDTAXGNAxoGen initiated with a Buy at Lake Street
Subscribe for More Information
November 24, 2014
07:05 EDTAXGNPDL BioPharma reports 9.3% passive stake in AxoGen
Subscribe for More Information
November 21, 2014
08:42 EDTETAKElephant Talk regains full compliance with NYSE MKT listing requirements
Elephant Talk Communications announced that it has received official notification from NYSE Regulation, dated November 20, that the company is now in compliance with the listing requirements. As a result of meeting the Exchange's listing standards, the company will be removed from the list of noncompliant issuers posted on the Exchange's website.
November 19, 2014
08:46 EDTPEDPacific Energy Development price target lowered to $1.20 from $2.75 at Roth Capital
Roth Capital cut its price target on Pacific Energy Development, citing the company 's weaker than expected Q3 results and lower oil prices. However, the firm thinks the stock is significantly undervalued at current levels and reiterates a Buy rating on the shares.
07:09 EDTABMDJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 18, 2014
09:06 EDTCDXCChromaDex initiated with a Buy at Sidoti
Subscribe for More Information
08:27 EDTETAKElephant Talk reports Q3 EPS (2c), consensus (1c)
Reports Q3 revenue $7.3M, consensus $8.23M.
November 14, 2014
07:02 EDTAXGNPDL BioPharma announces conclusion of revenue interest agreement with AxoGen
PDL BioPharma (PDLI) announced that the company has received $30.3M, in addition to previously received revenue interest payments, to conclude PDL's revenue interest agreement with AxoGen (AXGN). In October 2012, PDL entered into a structured financing transaction in which PDL provided AxoGen with an aggregate of $20.8M in exchange for royalties on certain AxoGen revenues.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use